Psoriasis: Ustekinumab and Other Biologics in the Pipeline

Noori Kim; Alice B. Gottlieb

doi:10.1007/s13671-012-0017-7

Psoriasis: Ustekinumab and Other Biologics in the Pipeline

Noori Kim, Alice B. Gottlieb

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th)17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.

Original language	English (US)
Pages (from-to)	108-114
Number of pages	7
Journal	Current Dermatology Reports
Volume	1
Issue number	3
DOIs	https://doi.org/10.1007/s13671-012-0017-7
State	Published - Sep 2012
Externally published	Yes

Keywords

Biologics
Briakinumab
Comorbidities
Cytokines
Dermatopharmacology
IL-12
IL-17
IL-22
IL-23
IL-23 inhibitors
IL-23/Th17 pathway
Immunology
Pathogenesis
Psoriasis
Psoriatic arthritis
T cells
T-cell modulators
TNF inhibitors
TNF-α
Therapy
Tumor necrosis factor-alpha
Ustekinumab

ASJC Scopus subject areas

Dermatology

Access to Document

10.1007/s13671-012-0017-7

Cite this

@article{822fb1786e9a4439a009a1b722c75dd5,

title = "Psoriasis: Ustekinumab and Other Biologics in the Pipeline",

abstract = "The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th)17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.",

keywords = "Biologics, Briakinumab, Comorbidities, Cytokines, Dermatopharmacology, IL-12, IL-17, IL-22, IL-23, IL-23 inhibitors, IL-23/Th17 pathway, Immunology, Pathogenesis, Psoriasis, Psoriatic arthritis, T cells, T-cell modulators, TNF inhibitors, TNF-α, Therapy, Tumor necrosis factor-alpha, Ustekinumab",

author = "Noori Kim and Gottlieb, {Alice B.}",

note = "Funding Information: N. Kim: None; A.B. Gottlieb: investigator for Abbott Laboratories, Amgen, Celgene Corporation, Immune Control, Janssen Biotech, Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, and UCB; consultant/advisory board member for Abbott Laboratories, Actelion, Amgen Astellas Pharma US, Beiersdorf, Bristol-Myers Squibb, Canfite, Celgene Corporation, Dermipsor, Incyte Corporation, Janssen Biotech, Lilly ICOS LLC, Merk & Co., Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, TEVA, and UCB; and research/educational grants from Abbott Laboratories, Amgen, Celgene Corporation, Janssen Biotech, Immune Control, Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, and UCB.",

year = "2012",

month = sep,

doi = "10.1007/s13671-012-0017-7",

language = "English (US)",

volume = "1",

pages = "108--114",

journal = "Current Dermatology Reports",

issn = "2162-4933",

publisher = "Springer US",

number = "3",

}

TY - JOUR

T1 - Psoriasis

T2 - Ustekinumab and Other Biologics in the Pipeline

AU - Kim, Noori

AU - Gottlieb, Alice B.

N1 - Funding Information: N. Kim: None; A.B. Gottlieb: investigator for Abbott Laboratories, Amgen, Celgene Corporation, Immune Control, Janssen Biotech, Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, and UCB; consultant/advisory board member for Abbott Laboratories, Actelion, Amgen Astellas Pharma US, Beiersdorf, Bristol-Myers Squibb, Canfite, Celgene Corporation, Dermipsor, Incyte Corporation, Janssen Biotech, Lilly ICOS LLC, Merk & Co., Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, TEVA, and UCB; and research/educational grants from Abbott Laboratories, Amgen, Celgene Corporation, Janssen Biotech, Immune Control, Novartis Pharmaceuticals, Novo Nordisk A/S, Pfizer, and UCB.

PY - 2012/9

Y1 - 2012/9

N2 - The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th)17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.

AB - The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th)17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.

KW - Biologics

KW - Briakinumab

KW - Comorbidities

KW - Cytokines

KW - Dermatopharmacology

KW - IL-12

KW - IL-17

KW - IL-22

KW - IL-23

KW - IL-23 inhibitors

KW - IL-23/Th17 pathway

KW - Immunology

KW - Pathogenesis

KW - Psoriasis

KW - Psoriatic arthritis

KW - T cells

KW - T-cell modulators

KW - TNF inhibitors

KW - TNF-α

KW - Therapy

KW - Tumor necrosis factor-alpha

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84973246781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973246781&partnerID=8YFLogxK

U2 - 10.1007/s13671-012-0017-7

DO - 10.1007/s13671-012-0017-7

M3 - Review article

AN - SCOPUS:84973246781

SN - 2162-4933

VL - 1

SP - 108

EP - 114

JO - Current Dermatology Reports

JF - Current Dermatology Reports

IS - 3

ER -

Psoriasis: Ustekinumab and Other Biologics in the Pipeline

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this